RxDoctor Payments Data

Parth Shah, MD

Vascular Surgery · New Britain, CTNPI 1225224017

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,659 of the $7,846 with a category attached, or 72.1%. 17 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 38.2% of the total. Reporting peaked in 2019 at $2,623 and has fallen 71.3% since, to $752 in 2025. That places this record below the midpoint for vascular surgery clinicians in CT, where the typical reported total is $7,252.

$7,846in general payments, 2019–2025

Across 75 payments — averaging $104.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$3K
  • Endologix LLC$1K
  • Silk Road Medical, Inc.$808
  • Medtronic$496
  • Inari Medical, Inc.$465
  • Bard Peripheral Vascular, Inc.$315
  • plus $1K from 11 others
$3,000in research payments, 2019–2025

Across 7 payments — averaging $428.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endologix LLC$3K

What the payments were for

  • Consulting fees$90011%
  • Travel & lodging$1,28716%
  • Food & beverage$5,65972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,846 in reported general payments places this provider in the 50th percentile of 82 vascular surgery providers in Connecticut.

See all vascular surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$156,675
Medicare patients
607
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$41,728
XareltoRivaroxaban45$39,456
ClopidogrelClopidogrel Bisulfate211$2,762
Atorvastatin Calcium113$1,162
Cilostazol36$787
Amlodipine Besylate24$156
Rosuvastatin Calcium12$143

Paid to pharmacies, not to this prescriber.

Other vascular surgery in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →